Other OTC - Delayed Quote USD

Bellerophon Therapeutics, Inc. (BLPH)

0.0562 0.0000 (0.00%)
At close: May 10 at 9:30 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Total Revenue
5,640.0000
--
--
--
Operating Expense
16,676.0000
22,384.0000
20,161.0000
26,276.0000
Operating Income
-11,036.0000
-22,384.0000
-20,161.0000
-26,276.0000
Net Non Operating Interest Income Expense
365.0000
135.0000
5.0000
-250.0000
Other Income Expense
--
1.0000
600.0000
-327.0000
Pretax Income
-10,530.0000
-22,248.0000
-19,556.0000
-26,853.0000
Tax Provision
-1,277.0000
-2,417.0000
-1,800.0000
-2,125.0000
Net Income Common Stockholders
-9,253.0000
-19,831.0000
-17,756.0000
-24,728.0000
Diluted NI Available to Com Stockholders
-9,253.0000
-19,831.0000
-17,756.0000
-24,728.0000
Basic EPS
-0.89
-2.08
-1.87
-3.17
Diluted EPS
-0.89
-2.08
-1.87
-3.17
Basic Average Shares
11,102.7710
9,550.8720
9,502.7930
7,797.1300
Diluted Average Shares
11,102.7710
9,550.8720
9,502.7930
7,797.1300
Total Operating Income as Reported
-11,036.0000
-22,384.0000
-20,161.0000
-26,276.0000
Total Expenses
16,676.0000
22,384.0000
20,161.0000
26,276.0000
Net Income from Continuing & Discontinued Operation
-9,253.0000
-19,831.0000
-17,756.0000
-24,728.0000
Normalized Income
-9,376.9006
-19,831.8910
-18,300.8000
-24,426.8330
Interest Expense
--
--
--
250.0000
Net Interest Income
365.0000
135.0000
5.0000
-250.0000
EBIT
-11,036.0000
-22,384.0000
-20,161.0000
-26,276.0000
EBITDA
-11,030.0000
-22,319.0000
-20,059.0000
-26,129.0000
Reconciled Depreciation
6.0000
65.0000
102.0000
147.0000
Net Income from Continuing Operation Net Minority Interest
-9,253.0000
-19,831.0000
-17,756.0000
-24,728.0000
Total Unusual Items Excluding Goodwill
141.0000
1.0000
600.0000
-327.0000
Total Unusual Items
141.0000
1.0000
600.0000
-327.0000
Normalized EBITDA
-11,171.0000
-22,320.0000
-20,659.0000
-25,802.0000
Tax Rate for Calcs
0.0001
0.0001
0.0001
0.0001
Tax Effect of Unusual Items
17.0994
0.1090
55.2000
-25.8330
12/31/2020 - 2/13/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TENX Tenax Therapeutics, Inc.
3.5500
0.00%
 
BNTC Benitec Biopharma Inc.
8.12
-12.22%
 
PULM Pulmatrix, Inc.
1.7800
-1.11%
 
KPRX Kiora Pharmaceuticals, Inc.
0.5097
+3.60%
 
ABOS Acumen Pharmaceuticals, Inc.
3.3600
0.00%
 
GEM.F GeNeuro SA
1.3650
-2.50%
 
OK10.F OKYO Pharma Limited
1.3600
0.00%
 
GENSF Genus plc
28.01
0.00%
 
PSH.DE Sernova Corp.
0.2392
-2.29%
 
GE91.DU Genmab A/S
27.00
+1.50%